ストックスクリーナーアプリを入手
1.25
8.09%
-0.11
アフターアワーズ：
1.26
0.01
+0.80%
Abvc Biopharma Inc (ABVC) 最新ニュース
ABVC Q1 2025 Earnings: Pre‑Revenue Biotech Reports Net Loss as Pipeline Development ContinuesSpecial Dividend Alert - thelegaladvocate.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Modest Loss Reported Amid Ongoing Clinical Development - thelegaladvocate.com
ABVC BioPharma Creeps Higher, Testing Resistance at $1.48Bullish Percent Index - thelegaladvocate.com
ABVC BioPharma Consolidates at $1.39 as Support and Resistance Levels NarrowPCR Divergence - thelegaladvocate.com
ABVC BioPharma Surges 13%: Key Levels and Potential ScenariosShort Term Trading Ideas - thelegaladvocate.com
ABVC BioPharma Inc. (ABVC) Edges Higher After Recent Pullback, Testing Key Resistance LevelIV Expansion Alert - Newser
ABVC BioPharma Inc. Q1 2025 Earnings: Narrowed Loss Highlights Continued Pipeline ProgressBuyback Announcement Report - thelegaladvocate.com
ABVC BioPharma Inc. (ABVC) Holds Steady Above Support After Modest GainSocial Flow Trades - Newser
ABVC BioPharma Reports Continued Losses and No Revenue in Q1 2026, Raising Doubts About Financial Stability - Minichart
Why Is ABVC BioPharma, Inc. (ABVC) Stock Up Today? - Meyka
Why Is ABVC BioPharma, Inc. (ABVC) Stock Down Today? - Meyka
ABVC BioPharma, Inc. 1Q 2026: Revenue ($1.55M), Net income ($1.56M), EPS ($0.06) — 10-Q Summary - TradingView
ABVC: Q1 2026 saw a $1.69M net loss, no revenue, and a $4.74M working capital deficit - TradingView
ABVC BioPharma (NASDAQ: ABVC) posts Q1 loss and going concern warning - Stock Titan
ABVC BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ABVC BioPharma Delays Quarterly SEC Filing - TipRanks
ABVC (ABVC) files Form 12b-25: late 10-Q for March 31, 2026 - Stock Titan
TradingKey - TradingKey
How sustainable is BioPharma (ABVC) profit margins? (Institutional Selling) 2026-05-08MACD Signals - newser.com
ABVC BioPharma drops 6.14% after Q1 2025 quarterly earnings post a 0.06 dollar per share loss with no prior analyst estimates.Management Guidance Update - newsline.com
ABVC BioPharma Inc. posts $0.06 EPS loss, no published estimatesROA Comparison - thelegaladvocate.com
BioPharma (ABVC) Stock: Why Industry Position (Pulls Back) 2026-04-15Breakout Signals - Cổng thông tin điện tử tỉnh Lào Cai
ABVC Options Volatility — NASDAQ:ABVC - TradingView
ABVC Options Chain — NASDAQ:ABVC - TradingView
Published on: 2026-04-10 10:41:09 - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Is BioPharma (ABVC) Stock Growing Now | Price at $1.33, Up 20.91%Trend Continuation Trade - thelegaladvocate.com
ABVC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
ABVC BioPharma Shareholders Back Board, Equity Plan Changes - TipRanks
ABVC BioPharma shareholders approve director slate and equity plan at annual meeting By Investing.com - Investing.com South Africa
ABVC BioPharma shareholders approve director slate and equity plan at annual meeting - Investing.com
ABVC BioPharma (ABVC) investors re-elect board and approve 2026 plan - stocktitan.net
ABVC BioPharma | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingmoomoo - Moomoo
Aug Weekly: What is ABVC BioPharma Incs market positionEarnings Summary Report & Precise Buy Zone Identification - baoquankhu1.vn
Bull Run: Is ABVC BioPharma Inc part of any major indexWeekly Stock Analysis & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Aug Breakouts: Can ABVC BioPharma Inc benefit from deglobalizationTrade Analysis Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
ABVC BioPharma (ABVC) plans 2026 virtual meeting, director votes and equity plan increase - Stock Titan
ABVC SEC FilingsAbvc Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ABVC BioPharma Reports 179% Asset Growth in 2025, Shifts Toward Hybrid Business Model - citybuzz -
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), ABVC BioPharma, Inc. has identified significant deficiencies in its internal control over financial reporting for the fiscal year 2025. - Bitget
ABVC BioPharma Reports 2025 Form 10-K - Yahoo Finance
ABVC BioPharmaquarterly period ended September, 2025 financial statements should not be relied upon - marketscreener.com
ABVC BioPharma (ABVC) restates Q3 2025 results and warns on going concern - Stock Titan
ABVC BioPharma (NASDAQ: ABVC) details biotech pipeline, risks and listing - Stock Titan
Restatement and asset surge reshape ABVC BioPharma (NASDAQ: ABVC) - Stock Titan
Sentiment Review: Should I buy ABVC BioPharma Inc stock nowJuly 2025 Setups & Verified Chart Pattern Signals - baoquankhu1.vn
ABVC BioPharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Can ABVC BioPharma Inc lead its sector in growthPortfolio Value Report & AI Enhanced Trading Signals - baoquankhu1.vn
ABVC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ABVC BioPharma Establishes BioKey Cayman Subsidiary as Part of Commercialization Strategy - citybuzz -
ABVC BioPharma Provides Corporate and Structural Update - Yahoo Finance
Tech Rally: Does ABVC BioPharma Inc have high return on assetsTrend Reversal & Daily Price Action Insights - baoquankhu1.vn
ABVC Should I Buy - Intellectia AI
Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Declines By 26.8% - Defense World
2.89%
大文字化:
|
ボリューム (24 時間):